BMC322 / Evogene - LARVOL DELTA

Biomica Reports Positive Results from Pre-Clinical Studies in its Inflammatory Bowel Disease (IBD) Program (PRNewswire) - "Biomica...a subsidiary of Evogene Ltd...reported today positive results from pre-clinical studies in its IBD program. In these studies, Biomica tested its optimized drug candidate BMC333, which consists of four live bacterial strains derived from Biomica's drug candidates BMC321 and BMC322, which had been previously tested as well. Treatment with these drug candidates demonstrated efficacy in several studies in reducing inflammation for the treatment of IBD...Looking forward, Biomica expects to begin the scale-up development processes of BMC333 in 2022, in preparation for the production of an initial clinical batch."

Preclinical • Immunology • Inflammatory Bowel Disease

[VIRTUAL] BMC322- A RATIONALLY-DESIGNED LIVE BACTERIAL CONSORTIUM BASED ON MICROBIOME FUNCTIONAL GENOMIC ANALYSIS FOR TREATMENT OF IBD (POSTER OF DISTINCTION) (CCCongress 2021) - "Most of the current data on the association between the intestinal microbiome and IBD is focusing on the intestinal microbial taxa and very little is known about the functionality of the microbiome in this condition.Aim: To construct a live bacterial consortium for reduction of intestinal inflammation in IBD based on a high-resolution functional microbial analysis, and its association with anti-inflammatory processes. Fecal metagenomics samples (n=581) and corresponding fecal calprotectin (FCP) levels from patients with Crohn's disease and Ulcerative Colitis were downloaded from the NCBI (SRA SRP057027, http://hmpdacc.org, SRA SRP002163 and SRP056641 (BioProject PRJNA275349)).Computational analysis was performed using PRISM (Biomica Ltd, Rehovot Israel), a proprietary metagenomics analysis platform integrating assembly-based and reference-based analyses for functional genomics profiling and utilizing BioCOGS, Biomica's internal comprehensive catalogue of..."

Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Biomica Announces Participation at the Crohn’s & Colitis Congress January 21-24, 2021 (Virtual Conference) (PRNewswire) - "Biomica Ltd...announced it will be featured as a presenting company at the Crohn's & Colitis Congress® to be held from today January 21-24, 2021...'BMC322 - A rationally-designed live bacterial consortium based on microbiome functional genomic analysis for treatment of IBD' on Saturday 23rd January, 2021 at 2PM (EST)."

Preclinical • Inflammatory Bowel Disease

Evogene: Q3 Update And Upcoming Catalysts (SeekingAlpha) - "Biomica Ltd. is advancing its rationally designed multi-strand live microbiome biotherapeutics programs in 3 main disease targets including:...IBD (inflammatory bowel disease); and...H1 2021 (my estimate) - Preclinical results released from BMC321 / BMC322 in treatment of IBD in studies currently being conducted at the University of North Carolina at the lab of Professor Balfour Sartor."

Preclinical • Inflammatory Bowel Disease